AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ABCL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.16B
- EPS (TTM)
- -$0.54
- Dividend yield
- None
- 52-week range
- 2.75 – 15.02
- Day range
- 12.56 – 13.45
- Volume / Avg
- 5.00M / 6.74M
- Beta
- —
- Shares outstanding
- 324.05M
- Next earnings
- Nov 9, 2026
52-week range
ABCL stock today
Shares of AbCellera Biologics (ABCL) finished lower on Oct 7 at $12.83, a drop of 2.43% or $0.32 per share, versus the S&P 500's 0.22% decline. At this level, ABCL sits near the top of its 52-week range of $2.75 to $15.02: 14.6% below the high, set on Sep 30, 2026 and 367.4% above the low. ABCL is up 275.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 122.4%.
AbCellera Biologics has posted a net loss over the last twelve months (EPS of -$0.54), so its P/E ratio is not meaningful. AbCellera Biologics's next earnings report is expected on Nov 9, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About AbCellera Biologics
Company profileAbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Carl L.G. Hansen Ph.D.
- Headquarters
- Vancouver, BC
- Employees
- 562
- IPO year
- 2020
- Website
- abcellera.com
Financial highlights
Full financialsIn fiscal 2025, AbCellera Biologics generated $75.1 million in revenue, up 160.6% from fiscal 2024. AbCellera Biologics reported a net loss of $146.4 million, compared with a loss of $162.9 million a year earlier. Operating margin was -289.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $75.13M | $28.83M | $38.02M | $485.42M | $375.20M |
| Growth | +160.56% | -24.17% | -92.17% | +29.38% | +60.92% |
| Net income | $-146.41M | $-162.86M | $-146.40M | $158.52M | $153.46M |
| EPS (diluted) | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$16.70+30.16%
- Strong buy 2
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 9, 2026
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-0.18 vs —
AbCellera Biologics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INDVIndivior Pharmaceuticals Inc. | 36.13 | +0.64% | $4.26B | vs ABCL |
| EWTXEdgewise Therapeutics Inc. | 39.57 | -1.12% | $4.30B | vs ABCL |
| TLXTelix Pharmaceuticals Limited ADR | 11.12 | +3.15% | $3.78B | vs ABCL |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs ABCL |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs ABCL |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs ABCL |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs ABCL |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs ABCL |
Indexes, lists and sector
AbCellera Biologics stock FAQ
What is AbCellera Biologics's stock price today?
ABCL last traded at $12.83 as of Oct 7, 4:00 PM EDT, down 2.43% on the day. Prices are delayed at least 15 minutes.
When is AbCellera Biologics's next earnings date?
AbCellera Biologics is expected to report earnings on Monday, November 9, 2026.
Who is AbCellera Biologics's CEO?
Dr. Carl L.G. Hansen Ph.D. is the chief executive officer of AbCellera Biologics Inc., which has about 562 employees.
What is the ABCL 52-week high?
The 52-week high for ABCL is $15.02 and the 52-week low is $2.75. The stock is currently 14.6% below its high.